VistaGen Therapeutics
VTGN
25 hedge funds and large institutions have $1.76M invested in VistaGen Therapeutics in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 24 → 25 (+1)
0.1% less ownership
Funds ownership: 0.3% → 0.19% (-0.1%)
57% less capital invested
Capital invested by funds: $4.09M → $1.76M (-$2.32M)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$68K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$61.7K |
| 3 |
BlackRock
New York
|
+$26.6K |
| 4 |
Koshinski Asset Management
Decatur,
Illinois
|
+$16.9K |
| 5 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$8.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$1.17M |
| 2 |
VF
Virtu Financial
New York
|
-$38.2K |
| 3 |
LPL Financial
San Diego,
California
|
-$31.6K |
| 4 |
CWA
Clarus Wealth Advisors
Peoria,
Arizona
|
-$16K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$10.1K |
VTGN Hedge Fund Activity: Q4 2019 in Review
25 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2019, worth a combined $1.76M — down 57% from $4.09M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VTGN positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 7 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $68K. The largest seller was William Blair & Company, cutting an estimated $1.17M.
- 25 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2019, up from 24 in Q3 2019.
- Funds reported $1.76M of VistaGen Therapeutics stock for Q4 2019, down 57% quarter-over-quarter.
- 4 funds opened new VistaGen Therapeutics positions in Q4 2019 and 3 closed out, a net change of +1 holder.
- The largest VistaGen Therapeutics buyer in Q4 2019 was Geode Capital Management, an estimated $68K added.
- The largest VistaGen Therapeutics seller in Q4 2019 was William Blair & Company, an estimated $1.17M sold.
Based on aggregated 13F filings for Q4 2019.